US2001026799A1PendingUtilityA1

Herpes simplex virus strains

51
Priority: Nov 20, 1998Filed: Apr 10, 2001Published: Oct 4, 2001
Est. expiryNov 20, 2018(expired)· nominal 20-yr term from priority
Inventors:Neal A. Deluca
C12N 15/86C07K 14/005C12N 2710/16643A61K 48/00C12N 7/00C12N 2710/16622
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides an HSV having a genome with a mutation of a TAATGARAT sequence such that, in the presence of a ICP4 gene product, a native immediate early gene is expressed from the genome with delayed kinetics, the genome having a further inactivating mutation of each of the genes encoding ICP4.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A herpes simlex virus (HSV) including a genome having a mutation of a TAATGARAT sequence such that, in the presence of HSV ICP4 gene product, a native immediate early gene is expressed from the genome with delayed kinetics, the genome having a further inactivating mutation of each of the genes encoding ICP4.  
     
     
         2 . The HSV of    claim 1   , which includes a further mutation.  
     
     
         3 . The HSV of    claim 2   , wherein the further mutation affects at least one of the ICP0, ICP22, ICP27, ICP47, ICP6, or UL41 loci.  
     
     
         4 . The HSV of    claim 1   , wherein the genome includes an exogenous gene.  
     
     
         5 . The HSV of    claim 2   , wherein the genome includes an exogenous gene.  
     
     
         6 . The HSV of    claim 3   , wherein the genome includes an exogenous gene.  
     
     
         7 . The HSV of    claim 4   , wherein the exogenous gene encodes a cytokine, cytosine deaminase, or thymadine kinase.  
     
     
         8 . The HSV of    claim 5   , wherein the exogenous gene encodes a cytokine, cytosine deaminase, or thymadine kinase.  
     
     
         9 . The HSV of    claim 6   , wherein the exogenous gene encodes a cytokine, cytosine deaminase, or thymadine kinase.  
     
     
         10 . A method of expressing a polynucleotide within a cell including infecting the cell with an HSV of    claim 4   .  
     
     
         11 . A method of expressing a polynucleotide within a cell including infecting the cell with an HSV of    claim 5   .  
     
     
         12 . A method of expressing a polynucleotide within a cell including infecting the cell with an HSV of    claim 6   .  
     
     
         13 . A composition for the administration of a mutant virus including an HSV of    claim 1    and a pharmacologically acceptable carrier.  
     
     
         14 . A composition for the administration of a mutant virus including an HSV of    claim 2    and a pharmacologically acceptable carrier.  
     
     
         15 . A composition for the administration of a mutant virus including an HSV of    claim 3    and a pharmacologically acceptable carrier.  
     
     
         16 . A composition for the administration of a mutant virus including an HSV of    claim 4    and a pharmacologically acceptable carrier.  
     
     
         17 . A composition for the administration of a mutant virus including an HSV of    claim 5    and a pharmacologically acceptable carrier.  
     
     
         18 . A composition for the administration of a mutant virus including an HSV of    claim 6    and a pharmacologically acceptable carrier.  
     
     
         19 . A composition for the administration of a mutant virus including an HSV of    claim 7    and a pharmacologically acceptable carrier.

Join the waitlist — get patent alerts

Track US2001026799A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.